Loading clinical trials...
Loading clinical trials...
A First in Human (FIH) Clinical Study to Assess Safety and Performance of Hepatic Sympathetic Denervation for Treatment of Inadequately Controlled Type 2 Diabetic Subjects on Oral Antihyperglycemic Agents.
Conditions
Interventions
Metabolic Neuromodulation System (MNS)
Locations
6
New Zealand
Auckland City Hospital
Auckland, New Zealand
Middlemore Hospital
Auckland, New Zealand
North Shore Hospital
Auckland, New Zealand
Christchurch Hospital
Christchurch, New Zealand
Dunedin Hospital
Dunedin, New Zealand
Wellington Hospital
Wellington, New Zealand
Start Date
October 1, 2014
Primary Completion Date
May 1, 2019
Completion Date
May 1, 2019
Last Updated
March 26, 2020
NCT05398783
NCT07224321
NCT07395050
NCT01399385
NCT07222137
NCT07536516
Lead Sponsor
Metavention
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions